Glaxosmithkline Intellectual Property Development Limited

United Kingdom


 
Total IP 738
Total IP Rank # 1,771
IP Activity Score 3.3/5.0    418
IP Activity Rank # 1,711
Parent Entity GlaxoSmithKline plc
Dominant Nice Class Pharmaceutical, veterinary and s...

Patents

Trademarks

221 0
109 0
403 5
0
 
Last Patent 2025 - Interleukin 5 binding protein do...
First Patent 2006 - Enzyme and receptor modulation
Last Trademark 2000 - Keppra levetiracetam
First Trademark 1999 - KEPPRA

Industry (Nice Classification)

Latest Inventions, Goods, Services

2024 Invention Il-7 binding proteins and their use in medical therapy. Provided herein are interleukin 7 (IL-7)...
Invention Heterocyclic compounds and their use in the treatment of mycobacterial infections. The invention ...
Invention Pi4kiiibeta inhibitors. The invention relates to compounds of formula (I) which are inhibitors o...
Invention Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an ...
Invention Compounds. The present invention relates to novel compounds that inhibit Lp-PLA2 activity, proce...
Invention Cytotoxicity targeting chimeras for car-t and car-nk cells. The present disclosure relates to het...
Invention Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies. The prese...
Invention Bispecific cytotoxicity targeting chimeras. The present disclosure relates to heterotrifunctional...
Invention Methods of treating chronic hepatitis b. The present disclosure relates to methods for treating a...
Invention Biopharmaceutical compositions and related methods. The present disclosure relates to compositio...
Invention System. The present invention relates to novel systems, polypeptides, compounds and methods. The ...
Invention Hydroxypyridoxazepines as nrf2 activators. The present invention relates hydroxypyridoxazepine c...
Invention Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors. The present invention relates...
Invention Methods of treating atopic dermatitis. The disclosure provides a method of treating atopic dermat...
Invention Cytotoxicity targeting chimeras for ccr2-expressing cells. The present disclosure relates to het...
2023 Invention Method of treating pain with an anti-ccl17 antibody. A method for treating chronic pain in a huma...
Invention Methods of treatment using b-cell maturation antigen antagonists. The disclosure provides methods...
Invention Treatment regimen. The present invention relates to a novel treatment method for the treatment o...
Invention Compounds useful in hiv therapy. The invention relates to compounds of Formula (I), (Ia), (II) o...
Invention Method for predicting production stability of clonal cell lines. The invention relates to a metho...
Invention Reduction or prevention of a malaria parasite or dengue virus transmission with 1 -methyl-9h-pyri...
Invention Reducing disease transmission of vector borne diseases. The present application relates to compou...
Invention Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors. The present invention relates ...
Invention Gepotidacin for use in the treatment of bacterial prostatitis. The present invention relates to m...
Invention Il-7 binding proteins and their use in medical therapy. Provided herein are interleukin 7 (IL-7) ...
Invention Antigen binding proteins and uses thereof. PlasmodiumPlasmodiumPlasmodium circumsporozoite protei...
Invention Combination treatment for cancer. Disclosed herein is a method of treating cancer, such as multi...
Invention Novel use. The present disclosure relates to an inhibitor of GPR91 for use in the treatment or p...
Invention Gepotidacin formulation. An oral formulation of, or comprising, granules of active pharmaceutical...
Invention Substituted pyridines as dnmt1 inhibitors. The invention relates to substituted pyridine derivat...
Invention Methods for purifying recombinant polypeptides. The present invention is directed to a novel proc...
Invention Chemical compounds. Provided are compounds and pharmaceutical compositions and uses thereof for ...
Invention Chemical compounds. vvv1.8 mediated diseases, such as pain and pain-associated diseases, and card...
Invention Nitrogen containing condensed 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors. Small mole...
Invention Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment. The present dis...
Invention Method for inactivation of sars-cov-2. The invention provides a method for inactivating SARS-CoV-...
Invention Method for assessing tcr t cell therapy designed to target an ny-eso-1 antigen. This document pro...
Invention Novel processes for the production of polynucleotides including oligonucleotides. The invention r...
Invention Pyrrol derivatives as inhibitors of apolipoprotein l-1. This invention relates to novel compounds...
2022 Invention Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic ...
Invention Display screen with graphical user interface
Invention Compounds useful in hiv therapy. The invention relates to compounds of Formula (I), (Ia), (Ib), ...
Invention Biopharmaceutical compositions and stable isotope labeling peptide mapping method. Disclosed her...
Invention Pharmaceutical compound. The present application relates to compounds of Formula (I) or a pharma...
Invention Oral solid dose formulations. Disclosed are novel pharmaceutical compositions comprising gepotid...
2021 Invention Interleukin 5 binding protein dosage regimen. The present disclosure relates to pharmaceutical c...
Invention Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors. Compounds of formul...
Invention Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 inf...
Invention Cathepsin inhibitors for preventing or treating viral infections. Provided are cathepsin inhibit...
2018 Invention Novel processes for the production of oligonucleotides. The invention relates to novel processes...
2002 G/S Pharmaceutical, veterinary and sanitary products; dietetic substances for medical use, food for ...
2000 G/S Pharmaceutical products and specialties acting on the central nervous system.